Phase iii data show port delivery system with ranibizumab enabled over 98% of patients to go six months between treatments for neovascular age-related macular degeneration

Genentech, a member of the roche group (six: ro, rog; otcqx: rhhby) today announced detailed results from the phase iii archway study evaluating its i
PDSB Ratings Summary
PDSB Quant Ranking